Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Up 3.5 %

NASDAQ PULM opened at $5.62 on Monday. The firm’s fifty day moving average price is $2.48 and its two-hundred day moving average price is $2.18. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $8.44. The firm has a market capitalization of $20.51 million, a P/E ratio of -2.13 and a beta of 0.99.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.